ClinicalTrials.gg
RecruitingNCT07183683ACULUTSUpdated Sep 19, 2025

Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction

An interventional study of group 1: electrical stimulation of acupuncture points plus routine care and group 2: acupressure plus routine care in Neurogenic Bladder Dysfunction, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Charite University, Berlin, Germany.

Planned enrollment
2nd of 14
150 · median 53
Started
2025
the only one that year
No phase
10 of 19
2 open now
Registered
18th of 19
by date

Among the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 18th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, or all of them as a file.
02

Study summary

Electrical vs. manual stimulation: The study compares two types of acupuncture - one using mild electrical currents and one using just manual no-needle techniques in the treatment of urinary bladder disfunction.

The study focuses on women diagnosed with multiple sclerosis (MS) who also have neurogenic bladder dysfunction - a condition where the bladder doesn't work properly due to nerve damage.

Read the detailed description

The objective of this study is to evaluate the feasibility, therapeutic effects, and safety of (A) electrical stimulation of acupuncture points (using a TENS device) in addition to routine care, and (B) manual stimulation of acupuncture points (using acupressure) in addition to routine care, compared to (C) routine care alone (control group), in female patients with multiple sclerosis (MS) and neurogenic bladder dysfunction.

Key outcome parameters include symptoms of neurogenic bladder dysfunction assessed using standardized patient-reported outcome measures.

Moreover, a qualitative substudy will be conducted to explore the subjectively perceived effects of the study interventions and the overall feasibility of the study. This will be carried out through semi-structured interviews and analyzed using qualitative research methodology.

03

Conditions studied

  • Neurogenic Bladder Dysfunction

Browse trials for

Keywords

  • multiple sclerosis
  • urinary bladder dysfunction
  • electrical stimulation
  • acupressure
  • acupuncture
  • posterior tibial nerve
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients, aged 18-60 years, with relapsing-remitting multiple sclerosis (RRMS) and an Expanded Disability Status Scale (EDSS) score ≤ 6
  • Stable immunomodulatory MS therapy for at least 3 months prior to enrollment
  • Presence of at least 3 out of the following 6 criteria indicative of overactive bladder dysfunction: urgency, daytime urinary frequency >10 times, nocturia >1 time per night, post-void dribbling, incontinence, or delayed initiation of micturition
  • Participants must be willing and cognitively and linguistically capable of adhering to the study protocol, performing the study interventions, and completing the required study documentation
  • Capacity to provide , and provision of written consent for both written and electronic data collection and participation in the study

Exclusion criteria

Exclusion Criteria:

  • Acute MS relapse within the last 3 months prior to individual study entry
  • Planned change in immunomodulatory therapy during the study period
  • Current need for regular self-catheterization (more than twice per week)
  • post-void residual volume, confirmed by ultrasound (>100 mL or >40% of pre-void volume)
  • Current or past history of bladder cancer
  • Implanted defibrillator or other pacemaker
  • Urogenital causes of bladder dysfunction, such as stress urinary incontinence or bladder prolapse
  • Spinal trauma within 5 years prior to study entry or any other pre-existing central nervous system disorders (e.g., stroke, Parkinson's disease), or history of pelvic, spinal, or bladder surgery
  • Acute urinary tract infection at the time of screening or within the previous 4 weeks
  • Urolithiasis or urogenital tumors within the past 6 months
  • Previous electrical posterior tibial nerve stimulation (TNS), acupuncture, or acupressure in the same anatomical region within 3 months prior to study entry
  • Regular pelvic floor training (more than twice per week) in the past 6 weeks or planned during the study period
  • Planned participation in another interventional clinical trial during the study period
  • Open wounds, edema, or lymphedema in the lower leg that may interfere with local intervention
  • Other serious pre-existing conditions (e.g., active cancer, heart failure, epilepsy, etc.) that contraindicate participation in the study
  • Obesity, defined as > 30
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    group 1: electrical stimulation of acupuncture points plus routine care

    Intervention is electrical stimulation of two acupuncture points at the inner ankle of the foot over the posterior tibialis nerve, stimulation twice daily over 5 weeks

    Device: group 1: electrical stimulation of acupuncture points plus routine care

  • Experimental
    group 2: acupressure plus routine care

    manual stimulation of the same two acupressure points over the inner ankle, stimulation twice daily over 5 weeks

    Other: group 2: acupressure plus routine care

  • No intervention
    group 3: routine care alone

    waiting list control

Interventions

  • Devicegroup 1: electrical stimulation of acupuncture points plus routine care

    The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min electrical stimulation per foot with 10Hz and an intensity up to individual tolerance level.

    Also known as: posterior tibial nerve stimulation

  • Othergroup 2: acupressure plus routine care

    The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min massage per foot

06

What researchers measure

Primary outcomes

  1. Incontinence Questionnaire Overactive Bladder (ICIQ-OAB)

    Bladder function scoring 0-16, higher values mean worse outcome

    Time frame: weeks 5 and 10 after the start of the intervention

Secondary outcomes

  1. Incontinence Quality of Life Measure (I-QoL)

    Disease-specific quality of life, scoring 1-110 , the higher the values the better

    Time frame: weeks 5 and 10 after the start of the intervention

  2. Patient's Global Impression of Change (PGIC)

    Subjective improvement of bladder dysfunction since start of the study, onedimenional scale with seven grades ranging from 'very much worse' to 'very much improved'

    Time frame: weeks 5 and 10 after the start of the intervention

  3. 3-day voiding diary

    Objective voiding parameters, including mean voiding frequency and average fluid intake to urine output ratio, assessing daytime urination frequency

    Time frame: weeks 5 and 10 after the start of the intervention

  4. 100mm Visual Analogue pain Scale (VAS) for last menstruation

    Pain during the most recent menstruation ranging from 0: no pain to 100: maximum pain

    Time frame: at weeks 5 and 10

Other outcomes

  1. rate of rescue medication

    rate of use of rescue medication (e.g., anticholinergics) and self-catheterization during trial participation

    Time frame: between weeks 1 and 5 and at week 10

  2. rate of adverse events

    the Safety of intervention will be assessed by recording the rate of adverse events and identification of adverse reactions

    Time frame: from week 1 to 10

07

Study locations

1 of 1 sites recruiting
  • Department for integrative medicine and prevention, Institute for social medicine, epidemiology and health economics, Charité university medicine Berlin
    Berlin, State of Berlin 10117, Germany
    Recruiting
08

References and documents

Publications

  • Al Dandan HB, Coote S, McClurg D. Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. Int J MS Care. 2020 Mar-Apr;22(2):91-99. doi: 10.7224/1537-2073.2019-030. PubMed 32410904 ↗
  • Chang KK, Wong TK, Wong TH, Leung AW, Chung JW. Effect of acupressure in treating urodynamic stress incontinence: a randomized controlled trial. Am J Chin Med. 2011;39(6):1139-59. doi: 10.1142/S0192415X11009469. PubMed 22083987 ↗
  • Marzouk MH, Darwish MH, El-Tamawy MS, Morsy S, Abbas RL, Ali AS. Posterior tibial nerve stimulation as a neuromodulation therapy in treatment of neurogenic overactive bladder in multiple sclerosis: A prospective randomized controlled study. Mult Scler Relat Disord. 2022 Dec;68:104252. doi: 10.1016/j.msard.2022.104252. Epub 2022 Oct 17. PubMed 36274285 ↗
  • Guitynavard F, Mirmosayyeb O, Razavi ERV, Hosseini M, Hosseinabadi AM, Ghajarzadeh M, Azadvari M. Percutaneous posterior tibial nerve stimulation (PTNS) for lower urinary tract symptoms (LUTSs) treatment in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Mult Scler Relat Disord. 2022 Feb;58:103392. doi: 10.1016/j.msard.2021.103392. Epub 2021 Nov 10. PubMed 35216773 ↗

Individual participant data

Plan to share: Yes — under reasonable request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: from 31.12.2027- 31.12.2032

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 15 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 19, 2025
StartEst.
Sep 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07183683
Responsible party
Benno Brinkhaus (Professor Dr. Benno Brinkhaus, Charite University, Berlin, Germany) — Principal investigator
First posted
Sep 19, 2025
Start date
Sep 2025 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 19, 2025

Study contacts

Benno Brinkhaus, PhD, MD
Contact
benno.brinkhaus@charite.de
+49 30 450 529 002
Joanna Dietzel, MD
Contact
joanna.dietzel@charite.de
+49 30 450 529 002

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion